JOP20220160A1 - مركبات فعّالة نحو مستقبلات نووية - Google Patents

مركبات فعّالة نحو مستقبلات نووية

Info

Publication number
JOP20220160A1
JOP20220160A1 JOP/2022/0160A JOP20220160A JOP20220160A1 JO P20220160 A1 JOP20220160 A1 JO P20220160A1 JO P20220160 A JOP20220160 A JO P20220160A JO P20220160 A1 JOP20220160 A1 JO P20220160A1
Authority
JO
Jordan
Prior art keywords
nuclear receptors
active towards
compounds active
towards nuclear
compounds
Prior art date
Application number
JOP/2022/0160A
Other languages
English (en)
Inventor
Sola Montserrat Erra
Santacana Llu?S Miquel Pages
Mart?Nez Lorena Taboada
Moll Joan Taltavull
Alex Haahr Gouliaev
Ian Sarvary
Luigi Piero Stasi
Glad Sanne Schr?Der
Thomas Franch
Javaloyes Juan Francisco Caturla
S?Ren Jensby Nielsen
Original Assignee
Nuevolution As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuevolution As filed Critical Nuevolution As
Publication of JOP20220160A1 publication Critical patent/JOP20220160A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

يتعلق الاختراع الحالي بمركبات مستقبلات نووية، تركيبات صيدلانية تحتوي على المركبات واستخدام المركبات في علاج.
JOP/2022/0160A 2019-12-20 2020-12-18 مركبات فعّالة نحو مستقبلات نووية JOP20220160A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962951221P 2019-12-20 2019-12-20
US202063064502P 2020-08-12 2020-08-12
PCT/IB2020/062227 WO2021124279A1 (en) 2019-12-20 2020-12-18 Compounds active towards nuclear receptors

Publications (1)

Publication Number Publication Date
JOP20220160A1 true JOP20220160A1 (ar) 2023-01-30

Family

ID=74003834

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0160A JOP20220160A1 (ar) 2019-12-20 2020-12-18 مركبات فعّالة نحو مستقبلات نووية

Country Status (18)

Country Link
US (2) US11685727B2 (ar)
EP (1) EP4076661A1 (ar)
JP (2) JP7106623B2 (ar)
KR (1) KR20220118425A (ar)
CN (1) CN114728170B (ar)
AU (1) AU2020408107A1 (ar)
BR (1) BR112022012205A2 (ar)
CA (1) CA3160508A1 (ar)
CL (1) CL2022001692A1 (ar)
CO (1) CO2022009510A2 (ar)
CR (1) CR20220355A (ar)
IL (1) IL291774A (ar)
JO (1) JOP20220160A1 (ar)
MX (1) MX2022007391A (ar)
PE (1) PE20230240A1 (ar)
TW (1) TW202128661A (ar)
UY (1) UY38994A (ar)
WO (1) WO2021124279A1 (ar)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022012260A (es) 2020-03-31 2022-11-30 Nuevolution As Compuestos activos frente a receptores nucleares.
MX2022012259A (es) 2020-03-31 2022-12-08 Nuevolution As Compuestos activos frente a receptores nucleares.
CN113461687B (zh) * 2021-08-10 2022-04-19 四川大学华西医院 2,8-氮杂-[4,5]十螺环酮衍生物及其制备方法和用途
CN116570589A (zh) * 2023-05-30 2023-08-11 南阳理工学院 化合物Parimifasor在制备抗肿瘤药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA92150C2 (ru) * 2004-06-04 2010-10-11 Арена Фармасьютикалз, Инк. Замещенные производные арила и гетероарила как модуляторы метаболизма и для профилактики и лечения связанных с ним расстройств
US7931909B2 (en) 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
UY34200A (es) 2011-07-21 2013-02-28 Bayer Ip Gmbh 3-(fluorovinil)pirazoles y su uso
DK3177612T3 (da) 2014-08-04 2022-05-16 Nuevolution As Eventuelt fusionerede heterocyclylsubstituerede derivater af pyrimidin, der er anvendelige til behandling af inflammatoriske, metaboliske, onkologiske og autoimmune sygdomme

Also Published As

Publication number Publication date
MX2022007391A (es) 2022-09-19
CA3160508A1 (en) 2021-06-24
UY38994A (es) 2021-07-30
EP4076661A1 (en) 2022-10-26
CL2022001692A1 (es) 2023-03-03
JP2023506357A (ja) 2023-02-16
CN114728170A (zh) 2022-07-08
CO2022009510A2 (es) 2022-07-08
BR112022012205A2 (pt) 2022-09-13
IL291774A (en) 2022-06-01
AU2020408107A1 (en) 2022-04-14
US11685727B2 (en) 2023-06-27
JP7106623B2 (ja) 2022-07-26
KR20220118425A (ko) 2022-08-25
US20210188807A1 (en) 2021-06-24
CR20220355A (es) 2022-09-23
WO2021124279A1 (en) 2021-06-24
US20230271937A1 (en) 2023-08-31
PE20230240A1 (es) 2023-02-07
TW202128661A (zh) 2021-08-01
CN114728170B (zh) 2024-03-01
JP2021098691A (ja) 2021-07-01

Similar Documents

Publication Publication Date Title
MX2022007391A (es) Compuestos activos frente a receptores nucleares.
CA2956871C (en) Compounds active towards bromodomains
CR20200064A (es) Carboxamidas como moduladores de los canales de sodio
MX2022007265A (es) Compuestos activos frente a receptores nucleares.
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MY192088A (en) Combinantion therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
PH12020551934A1 (en) Magl inhibitors
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2019001322A (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
MX2023001963A (es) Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino.
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
MX2019011545A (es) Composiciones celulares y de andamio inyectables.
MX2022005132A (es) Terapia combinada con formulaciones de anticuerpos anti-pvrig y anticuerpos anti-pd-1.
GEP20247585B (en) Furoindazole derivatives
MX2020011756A (es) Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
PH12021551138A1 (en) Application of chidamide in combination with r-chop, and drug combination
MX2018005350A (es) Formulacion de combinacion de dosis fija, eflornitina y sulindaco.
MX2021008941A (es) Moduladores gpr35.
PH12019501820A1 (en) Pharmaceutical compositions for combination therapy
PH12018502139A1 (en) Phosphaplatin liquid formulations
MX2023009527A (es) Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.